DERIVATIVE LIABILITIES (Details) - USD ($)		9 Months Ended
	Mar. 31, 2022	Sep. 30, 2025	Sep. 30, 2024
Derivative Liabilities [Line Items]
Conversion of Stock, Shares Converted (in Shares)	18,473
Sale of stock, percentage of ownership	19.90%
Milestone Payment		$ 10,000,000
Redemption term.		For the period ending upon the earlier of (i) 10 years after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to 3.5% of the Company’s net sales (the “Royalty”) on a quarterly basis, where “Net Sales” has the same meaning as in the Company’s license agreement with the U.S. Army for tafenoquine.
Royalty percentage		3.50%
(Gain) loss on change in fair value of derivative liabilities		$ (156,445)	$ 1,683,034
Series A Non-Voting Convertible Preferred Stock [Member]
Derivative Liabilities [Line Items]
Designated shares (in Shares)	80,965	80,965